Conduit Pharmaceuticals has partnered with Charles River Laboratories to evaluate its lead compound AZD1656 in a preclinical Systemic Lupus Erythematosus model, with results expected in Q2 2025.
Conduit Pharmaceuticals successfully completed Phase I of its strategic collaboration with Sarborg Limited, establishing foundations for AI integration in drug development processes.
The Japan Patent Office has granted Conduit Pharmaceuticals a composition of matter patent for AZD1656, a Glucokinase Activator targeting autoimmune disorders including Lupus and ANCA Vasculitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.